公开(公告)号：US20110152297A1

公开(公告)日：2011-06-23

申请号：US11884923

申请日：2006-02-24

Applicant: Christopher Thomas Halsall ,  Laurent Francois Andre Hennequin ,  Alleyn Thomas Plowright ,  Richard Storey ,  Kieran Lennon

Inventor： Christopher Thomas Halsall ,  Laurent Francois Andre Hennequin ,  Alleyn Thomas Plowright ,  Richard Storey ,  Kieran Lennon

IPC: A61K31/517 ,  C07D401/12 ,  A61P35/00

CPC classification number: C07D401/12

Abstract: The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.

Abstract translation: 本发明涉及式I的喹唑啉衍生物或其药学上可接受的盐：其中R1，R2，R3，R4和m各自如说明书中所定义; 其准备过程; 含有它们的药物组合物及其在制备用于提供抗增殖作用的药物中的用途。 预期式I的喹唑啉衍生物可用于治疗疾病，例如由erbB受体酪氨酸激酶介导的某些癌症，以及例如EGFR酪氨酸激酶。

公开(公告)号：US08735410B2

公开(公告)日：2014-05-27

申请号：US11884923

申请日：2006-02-24

Applicant: Christopher Thomas Halsall ,  Laurent Francois Andre Hennequin ,  Alleyn Thomas Plowright ,  Richard Storey ,  Kieran Lennon

Inventor： Christopher Thomas Halsall ,  Laurent Francois Andre Hennequin ,  Alleyn Thomas Plowright ,  Richard Storey ,  Kieran Lennon

IPC: A01N43/54 ,  A61K31/517

CPC classification number: C07D401/12

Abstract: The invention concerns quinazoline derivatives of the Formula I, or pharmaceutically acceptable salts thereof: wherein each of R1, R2, R3, R4 and m are as defined in the description; processes for their preparation; pharmaceutical compositions containing them and their use in the manufacture of a medicament for providing an anti-proliferative effect. The quinazoline derivatives of Formula I are expected to be useful in the treatment of diseases such as certain cancers mediated by erbB receptor tyrosine kinases, and, for example, EGFR tyrosine kinase.

Abstract translation: 本发明涉及式I的喹唑啉衍生物或其药学上可接受的盐：其中R1，R2，R3，R4和m各自如说明书中所定义; 其准备过程; 含有它们的药物组合物及其在制备用于提供抗增殖作用的药物中的用途。 预期式I的喹唑啉衍生物可用于治疗疾病，例如由erbB受体酪氨酸激酶介导的某些癌症，以及例如EGFR酪氨酸激酶。